BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

941 related articles for article (PubMed ID: 29168933)

  • 21. A systematic overview of chemotherapy effects in non-small cell lung cancer.
    Sörenson S; Glimelius B; Nygren P;
    Acta Oncol; 2001; 40(2-3):327-39. PubMed ID: 11441939
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chemotherapy for non-small-cell lung carcinoma: from a blanket approach to individual therapy.
    Reungwetwattana T; Eadens MJ; Molina JR
    Semin Respir Crit Care Med; 2011 Feb; 32(1):78-93. PubMed ID: 21500127
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjuvant Chemotherapy for Early-Stage Non-small Cell Lung Cancer.
    Visbal AL; Leighl NB; Feld R; Shepherd FA
    Chest; 2005 Oct; 128(4):2933-43. PubMed ID: 16236970
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adjuvant cisplatin-based chemotherapy for resected NSCLC: one size fits all?
    Geiger S; Schlemmer M; Heinemann V; Stemmler HJ
    Anticancer Drugs; 2010 Oct; 21(9):799-804. PubMed ID: 20679887
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adjuvant and neoadjuvant chemotherapy in NSCLC: a paradigm shift.
    Betticher DC
    Lung Cancer; 2005 Dec; 50 Suppl 2():S9-16. PubMed ID: 16557669
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined modality therapy of non-small cell lung cancers.
    Juretic A; Sobat H; Samija M
    Ann Oncol; 1999; 10 Suppl 6():93-8. PubMed ID: 10676559
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adjuvant therapy in early-stage non-small cell lung cancer.
    Serke M
    Front Radiat Ther Oncol; 2010; 42():135-144. PubMed ID: 19955799
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjuvant and neoadjuvant therapy for early-stage non-small-cell lung cancer.
    Choong NW; Vokes EE
    Clin Lung Cancer; 2005 Dec; 7 Suppl 3():S98-104. PubMed ID: 16384544
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of adjuvant chemotherapy in NSCLC (stages I to III).
    Coleman MH; Bueno R
    Surg Oncol Clin N Am; 2011 Oct; 20(4):757-67. PubMed ID: 21986270
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adjuvant chemotherapy for completely resected non-small-cell lung cancer.
    Suehisa H; Toyooka S
    Acta Med Okayama; 2009 Oct; 63(5):223-30. PubMed ID: 19893597
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adjuvant therapy for nonsmall cell lung cancer: recent advances and future perspectives.
    Pakkala S; Ramalingam SS
    Curr Opin Oncol; 2016 Mar; 28(2):150-8. PubMed ID: 26809014
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Postoperative adjuvant therapy for completely resected early-stage non-small cell lung cancer.
    Kato H; Tsuboi M; Kato Y; Ikeda N; Okunaka T; Hamada C
    Int J Clin Oncol; 2005 Jun; 10(3):157-64. PubMed ID: 15990962
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Integrated management of stage III in nonsmall cell lung cancer: where do perioperative chemotherapy and immunotherapy fit?
    Collazo-Lorduy A; Blanco M; Calvo V; Provencio M
    Curr Opin Pulm Med; 2024 Jul; 30(4):346-351. PubMed ID: 38712693
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimal adjuvant therapy for non-small cell lung cancer--how to handle stage I disease.
    Wakelee H; Dubey S; Gandara D
    Oncologist; 2007 Mar; 12(3):331-7. PubMed ID: 17405898
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Three-Year Follow-Up of a Randomized Phase II Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine (the TREAT Study).
    Kreuter M; Vansteenkiste J; Fischer JR; Eberhardt WE; Zabeck H; Kollmeier J; Serke M; Frickhofen N; Reck M; Engel-Riedel W; Neumann S; Thomeer M; Schumann C; De Leyn P; Graeter T; Stamatis G; Griesinger F; Thomas M;
    J Thorac Oncol; 2016 Jan; 11(1):85-93. PubMed ID: 26762743
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Non-small cell lung cancer: adjuvant and neo-adjuvant chemotherapy.
    Brahmer JR; Ettinger DS
    Respirology; 2007 May; 12(3):320-5. PubMed ID: 17539833
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune Checkpoint Inhibitors in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer.
    Puri S; Shafique M; Gray JE
    Curr Treat Options Oncol; 2018 Jun; 19(8):39. PubMed ID: 29931587
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical issues in the management of non-small-cell lung cancer and the role of platinum-based therapy.
    Socinski MA
    Clin Lung Cancer; 2004 Mar; 5(5):274-89. PubMed ID: 15086966
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO).
    Sands JM; Mandrekar SJ; Kozono D; Oxnard GR; Hillman SL; Wigle DA; Govindan R; Carlisle J; Gray J; Salama JK; Raez L; Ganti A; Foster N; Malik S; Bradley J; Kelly K; Ramalingam SS; Stinchcombe TE
    Immunotherapy; 2021 Jun; 13(9):727-734. PubMed ID: 33878954
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Resected non-small-cell lung cancer stage I/II: indication for adjuvant/neoadjuvant therapy?
    Hoffmann H
    Lung Cancer; 2004 Aug; 45 Suppl 2():S91-7. PubMed ID: 15552788
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 48.